Clinical core biopsy of locally advanced breast cancer performed in the physician's office without image guidance: Expedited pathway to diagnosis

被引：0
|
作者：
Wong, F.
Martin, L. A.
Pansegrau, G. K.
Sherriff, C.
Singh-Carlson, S.
机构：
[1] British Columbia Canc Agcy, Fraser Valley Ctr, Surrey, BC, Canada
[2] Calif State Univ Long Beach, Long Beach, CA 90840 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11525
引用
收藏
页数：1
相关论文
共 44 条
  • [41] HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)
    Miller, K.
    Cortes, J.
    Hurvitz, S. A.
    Krop, I. E.
    Tripathy, D.
    Verma, S.
    Riahi, K.
    Reynolds, J. G.
    Wickham, T.
    Molnar, I.
    Yardley, D. A.
    [J]. CANCER RESEARCH, 2016, 76
  • [42] HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
    Miller, Kathy
    Cortes, Javier
    Hurvitz, Sara A.
    Krop, Ian E.
    Tripathy, Debu
    Verma, Sunil
    Riahi, Kaveh
    Reynolds, Joseph G.
    Wickham, Thomas J.
    Molnar, Istvan
    Yardley, Denise A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
    Rugo, H. S.
    Niyazov, A.
    Bhattacharyya, H.
    Arondekar, B.
    Hurvitz, S. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S480 - S480
  • [44] Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM/2012-07)
    Ciruelos, E.
    Gonzalez, E.
    Lluch, A.
    Garrigos, L.
    Quiroga, V.
    Anton, A.
    Pascual, T.
    Montano, A.
    Angulo, M. dM
    Camara, M. dC
    Amigo, Y.
    Carrasco, E.
    Casas, A.
    [J]. CANCER RESEARCH, 2016, 76
12345